JPWO2019198731A1 - 抗体断片及び該抗体断片を含む二重特異性抗体 - Google Patents

抗体断片及び該抗体断片を含む二重特異性抗体 Download PDF

Info

Publication number
JPWO2019198731A1
JPWO2019198731A1 JP2020513417A JP2020513417A JPWO2019198731A1 JP WO2019198731 A1 JPWO2019198731 A1 JP WO2019198731A1 JP 2020513417 A JP2020513417 A JP 2020513417A JP 2020513417 A JP2020513417 A JP 2020513417A JP WO2019198731 A1 JPWO2019198731 A1 JP WO2019198731A1
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nos
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513417A
Other languages
English (en)
Japanese (ja)
Inventor
光央 梅津
光央 梅津
在生人 杉山
在生人 杉山
光 中澤
光 中澤
哲平 二井手
哲平 二井手
英博 岸本
英博 岸本
明一 村上
明一 村上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
University of the Ryukyus NUC
Original Assignee
Tohoku University NUC
University of the Ryukyus NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, University of the Ryukyus NUC filed Critical Tohoku University NUC
Publication of JPWO2019198731A1 publication Critical patent/JPWO2019198731A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020513417A 2018-04-10 2019-04-09 抗体断片及び該抗体断片を含む二重特異性抗体 Pending JPWO2019198731A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018075339 2018-04-10
JP2018075339 2018-04-10
PCT/JP2019/015528 WO2019198731A1 (fr) 2018-04-10 2019-04-09 Fragment d'anticorps et anticorps bispécifique comprenant ledit fragment d'anticorps

Publications (1)

Publication Number Publication Date
JPWO2019198731A1 true JPWO2019198731A1 (ja) 2021-04-22

Family

ID=68164195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513417A Pending JPWO2019198731A1 (ja) 2018-04-10 2019-04-09 抗体断片及び該抗体断片を含む二重特異性抗体

Country Status (2)

Country Link
JP (1) JPWO2019198731A1 (fr)
WO (1) WO2019198731A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023047557A1 (fr) 2021-09-27 2023-03-30 国立大学法人東北大学 Procédé de conception de protéine par apprentissage automatique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
２０１７年度 生命科学系学会合同年次大会要旨集, 1P-1359, JPN7019002209, ISSN: 0005124016 *

Also Published As

Publication number Publication date
WO2019198731A1 (fr) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7341185B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
US12421292B2 (en) Anti-DLL3 chimeric antigen receptors and uses thereof
EP3130607B1 (fr) Anticorps du muc1*
Yazaki et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
WO2017197667A1 (fr) Anticorps monoclonal humanisé anti-pd-l1 humaine et son utilisation
JP2022553464A (ja) 多重特異性抗体とその製造方法および使用
WO2012020622A1 (fr) Fragment de fragment variable substitué par une lysine d'anticorps humanisé anti-egfr et son utilisation
EP2412808B1 (fr) Anticorps bispécifique du type lh
EP2006379A1 (fr) Anticorps bispecifique hautement fonctionnel
CN104558192B (zh) 一种双特异性抗体her2xcd3的构建及应用
JP2003518391A (ja) エピトープに結合可能な蛋白質の変異体のライブラリーから発達した結合メンバーを選抜するために天然型エピトープを使用する方法
WO2017070943A1 (fr) Anticorps bispécifique, et procédé de fabrication et d'utilisation correspondant
WO2015146438A1 (fr) Anticorps bispécifique ciblant le récepteur du facteur de croissance épidermique humain
CN111995685B (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
WO2023273595A1 (fr) Anticorps se liant à trop2, anticorps bispécifique ciblant trop2 et cd3, procédés de préparation associés et utilisations correspondantes
Schlapschy et al. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach
WO2015172341A1 (fr) Anticorps bispecifique dirige contre le glypicane 3 et un antigene de lymphocyte t
TW202039577A (zh) 截斷的多價多元體
JPWO2019198731A1 (ja) 抗体断片及び該抗体断片を含む二重特異性抗体
Moradi-Kalbolandi et al. Soluble expression and characterization of a new scFv directed to human CD123
AU2024293248A1 (en) Anti-HER2 single-domain antibody, and preparation method therefor and use thereof
WO2023222035A1 (fr) Protéine de fusion d'un anticorps anti-tigit et de l'il-2 ou variant de celle-ci, et son application
JP2022512724A (ja) 抗ｃｄ１３７抗体およびその使用
JP2005333993A (ja) 新規なダイアボディ型二重特異性抗体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230808